Targeted Oncology Staff

During a Targeted Oncology™ Case-Based Roundtable™ event, Maria Bell, MD, MPH, MBA, moderated a discussion on biomarker testing and treatment for a patient with extensive, well-differentiated, grade 1 endometrioid adenocarcinoma.

During a Targeted Oncology™ Case-Based Roundtable™ event, Sandip P. Patel, MD, and other oncologists discussed the role of chemotherapy plus dual immunotherapy in patients with non–small cell lung cancer.

At a live virtual event, David Rizzieri, MD, CPE, provided commentary on the landscape of treatment for patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL).

In the second part of a 2-article series, Matthew A. Lunning, DO, FACP, leads a discussion on how to best manage toxicities from tafasitamab and lenalidomide for patients with relapsed/refractory diffuse large B-cell lymphoma.

During a Targeted Oncology™ Case-Based Roundtable™ event, Raajit K. Rampal, MD, gave an overview of the classification, risk assessment, and current therapy options for patients with myelofibrosis.

In the second article of a 2-part series, Sameer A. Parikh, MBBS, looks at the risk of cardiac related toxicities with zanubrutinib for patients with relapsed chronic lymphocytic leukemia.

During a Targeted Oncology™ Case-Based Roundtable™ event, Rana McKay, MD, moderated a discussion on what role risk stratification plays in selecting frontline therapy for a patient with metastatic renal cell carcinoma. This is the first of 2 articles based on this event.

During an in-person Community Case Forum event in New Jersey, Thomas Herzog, MD, and various participants discussed their approaches to molecular testing and treatment for patients with recurrent endometrial cancer.

In the second article of a 2-part series, Komal Jhaveri, MD, leads a discussion on the considerations physicians must have when looking to give elacestrant to patients with estrogen receptor–positive, HER2 negative metastatic breast cancer.

In separate virtual live events, R. Kate Kelley, MD, with Daneng Li, MD, and Chih-Yi (Andy) Liao, MD, with Anjana Pillai, MD, discussed imaging and treatment for a patient with biliary tract cancer with event participants.

During a Targeted Oncology™ Case-Based Roundtable™ event, Evan J. Lipson, MD, and participants discussed tolerability factors that could influence the choice of frontline immunotherapy regimen for a patient with metastatic melanoma.

During a Targeted Oncology™ Case-Based Roundtable™ event, Mark S. Shahin, MD, discussed with participants how they use the individualized dose of niraparib and manage adverse events in patients with advanced ovarian cancer.

During a Targeted Oncology™ Case-Based Roundtable™ event, Justin Kline, MD, discussed the importance of the ELEVATE-TN trial of acalabrutinib in treating a patient with chronic lymphocytic leukemia.

During a Targeted Oncology™ Case-Based Roundtable™ event, Bart Scott, MD, discussed JAK inhibitor options and the data from the PERSIST-2 trial of pacritinib. This is the first of 2 articles based on this event.

In an interview, Martin F. Dietrich, MD, PhD, discussed his observations on the latest and upcoming trials that target biomarkers in earlier-stage non–small lung cancer.

In the second part of a 2-article series, Matthew Matasar, MD, MS, discusses long-term follow up data from the LOTIS-2 trial and how these data show the durability and tolerability of loncastuximab for patients with relapsed/refractory diffuse large B-cell lymphoma.

At a live virtual event, Jack Khouri, MD, discussed how treatment options for patients with relapsed/refractory multiple myeloma have evolved with the use of bispecific antibodies giving physicians the opportunity to target BCMA and GPRC5D on the plasma cell.

During a Targeted Oncology™ Case-Based Roundtable™ event, Sumanta K. Pal, MD, and participants explored the third-line treatment options for a patient with advanced renal cell carcinoma. This is the second of 2 articles based on this event.

In the second article of a 2-part series, Douglas Sborov, MD, discusses the toxicities seen with isatuximab and how this therapy can impact patients in rural areas relying on community center treatment.

During a Targeted Oncology™ Case-Based Roundtable™ event, Balazs Halmos, MD, discussed with participants how they interpret the ADAURA trial and the approach to adjuvant targeted therapy in non–small cell lung cancer This is the second of two articles based on this event.

In the first part of a 2-article series, Matthew A. Lunning, DO, FACP, takes into consideration the perspectives of his peers on the use of tafasitamab and lenalidomide for patients with relapsed/refractory diffuse large B-cell lymphoma.

During a Targeted Oncology™ Case-Based Roundtable™ event, Sumanta K. Pal, MD, discussed the case of an older patient with metastatic renal cell carcinoma who had recurrent disease after receiving axitinib and pembrolizumb, then single-agent cabozantinib. This is the first of 2 articles based on this event.

In the first article of a 2-part series, Lori Muffly, MD, MS, discusses with a panel of physicians what their approach is to identifying patients with severe chronic graft-versus-host-disease and how they treat them in conjunction with the transplant team.

During a Targeted Oncology™ Case-Based Roundtable™ event, Mansi R. Shah, MD, discussed the impact of the MagnetisMM-1 and MagnetisMM-3 trials of elranatamab in patients with relapsed/refractory multiple myeloma. This is the second of 2 articles based on this event.

In this Q&A discussion, Hans Hammers, MD, PhD, explains the rationale for continued use of tyrosine kinase inhibitor and PD-L1 therapy combinations, like lenvatinib and pembrolizumab, for patients with advanced renal cell carcinoma.

During a Targeted Oncology™ Case-Based Roundtable™ event, Neeraj Agarwal, MD, discussed his approach to recognizing and managing adverse events related to treatment with cabozantinib and nivolumab in patients with advanced renal cell carcinoma. This is the second article based on this event.

In the first article of a 2-part series, Sameer A. Parikh, MBBS, discusses the makeup and design of the phase 3 ALPINE study that showed the promise for the next-generation Bruton tyrosine kinase inhibitor zanubrutinib.

During a Targeted Oncology™ Case-Based Roundtable™ event, Amitkumar Mehta, MD, discussed what regimens are available for patients who progressed after 2 prior lines of therapy for diffuse large B-cell lymphoma, and what tolerability concerns there are for these regimens.

In the first article of a 2-part series, Komal Jhaveri, MD, guides a conversation on treatment options for patients with ESR1-positive metastatic breast cancer.

During a Targeted Oncology™ Case-Based Roundtable™ event, Haris Ali, MD, and participants discussed dosing of JAK inhibitors therapy and how the survival data for ruxolitinib compares with that of momelotinib. This is the second of 2 articles based on this event.